Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Variance and Confidence Interval Estimation in Small-Sample Propensity Score Analyses: Bootstrap Versus Asymptotic Methods.

Statistics in medicine·2026
Same author

Prognostic value of [<sup>18</sup>F]fluorodeoxyglucose PET/CT in esophageal cancer patients treated with anti-PD-1 inhibitors.

BMC medical imaging·2026
Same author

Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC.

Frontiers in oncology·2026
Same author

The Implication of Failure Patterns After Neoadjuvant Chemoradiation Therapy With Small Involved Field in Esophageal Squamous Cell Carcinoma.

Practical radiation oncology·2026
Same author

Phase II Efficacy and Safety of Pembrolizumab with Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients with Untreated, Asymptomatic Brain Metastasis (PHOEBS).

Cancer research and treatment·2026
Same author

Treatment patterns and clinical outcomes in real-world patients with small-cell lung cancer in South Korea: A single-center experience.

International journal of cancer·2026
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K

Randomized Phase II Cancer Clinical Trials to Validate Predictive Biomarkers.

Baoshan Zhang1, Jong-Mu Sun2, Myung-Ju Ahn2

  • 1Department of Biostatistics and Bioinformatics, Duke University, Durham, NC 27705, USA.

Biomedicines
|October 26, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for designing and analyzing phase II cancer clinical trials to validate predictive biomarkers. The approach ensures robust sample size selection and analysis strategies for biomarker-stratified trials.

Keywords:
interactionlogistic regressionsample size calculationstratified randomization trial

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Related Experiment Videos

Last Updated: Jun 9, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

16.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biomarker Validation

Background:

  • Designing cancer clinical trials with biomarkers requires careful consideration of trial phase, biomarker type, and validation status.
  • Phase II trials are crucial for validating predictive biomarkers to guide targeted therapies.

Purpose of the Study:

  • To present a method for designing and analyzing phase II cancer clinical trials focused on validating predictive biomarkers.
  • To provide a practical approach for biomarker validation within clinical trial settings.

Main Methods:

  • A randomized trial design is proposed, stratifying patients by biomarker status and allocating them to targeted or non-targeted therapy.
  • Tumor response serves as the primary endpoint for biomarker validation via interaction testing.
  • A sample size calculation method is developed, considering both logit-transformed and raw response rates.

Main Results:

  • The proposed sample size method was applied to a real-world randomized phase II trial.
  • Simulations demonstrated the robust performance of the test statistic and sample size method across various scenarios.

Conclusions:

  • The developed method offers a practical framework for validating predictive biomarkers in phase II cancer trials.
  • Simulation results support the chosen interaction models and provide guidance for sample size and analysis in biomarker-stratified trials.